Yanan Zhu
Stock Analyst at Wells Fargo
(0)
# 4678
Out of 5,327 analysts
88
Total ratings
25.00%
Success rate
-20.87%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
SRPT Sarepta Therapeutics | Initiates Coverage On: Overweight | 115 | 61.53 | 86.9% | 1 | Apr 11, 2025 | |
RGLS Regulus Therapeutics | Upgrades: Overweight | 3 6 | 3.5 | 71.43% | 1 | Mar 27, 2025 | |
ADAP Adaptimmune Therapeu... | Maintains: Equal-Weight | 2 2 | 0.28 | 435.71% | 2 | Mar 21, 2025 | |
AUTL Autolus Therapeutics | Maintains: Overweight | 8 6 | 1.4 | 328.57% | 3 | Mar 21, 2025 | |
MGX Metagenomi | Maintains: Overweight | 25 20 | 1.7 | 1076.47% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 12 10 | 3.54 | 182.49% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 58 50 | 12.84 | 289.41% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 5 4 | 1.25 | 220% | 3 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 35 30 | 13.95 | 115.05% | 2 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 60 50 | n/a | n/a | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 40 5 | 4.18 | 19.62% | 8 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 15 | 0.99 | 1415.15% | 6 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 7 4 | 1.57 | 154.78% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 17 4 | n/a | n/a | 4 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 82 77 | 29.77 | 158.65% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 35 40 | n/a | n/a | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 70 65 | 37.88 | 71.59% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 30 | 3.88 | 673.2% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 22 25 | 3.62 | 590.61% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 50 50 | 31.21 | 60.21% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 10 | n/a | n/a | 2 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 9 13 | n/a | n/a | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 5 4 | 0.74 | 440.54% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 30 24 | n/a | n/a | 1 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 450 | 2.4 | 18650% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 125 105 | 19.83 | 429.5% | 2 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 14 10 | 1.8 | 455.56% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 1 1 | n/a | n/a | 2 | Oct 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 272 326 | 620.72 | -47.48% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 79 70 | n/a | n/a | 2 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 48 53 | n/a | n/a | 2 | Aug 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 122 133 | n/a | n/a | 4 | May 7, 2020 |